Public Procurement of Medicines in Europe: Key Findings and Best Practices
Experts in the Pharmacoeconomics Department recently conducted a study on the best practices in the public procurement of medicines. Commissioned by the European Commission, this study aims to improve access to medicines, affordability, availability, and more.
Public procurement of medicines can improve access, foster competition, and address important policy objectives. This study mapped and analyzed PPM practices across 32 European countries, revealing some fascinating insights.
Findings include:
- Different organizational forms of procurement, ranging from facility-based to centralized procurement.
- Use of various procedures and techniques, including the Most Economically Advantageous Tender
- Specific forms of procurement in the hospital sector
- Impacts on policy objectives, such as access to medicines and environmental protection
- Best practices for optimizing PPM in Europe
Discover the full report for a comprehensive understanding of PPM practices in Europe on the below link. Let’s work together to ensure affordable and accessible medicines for all!
Recent Posts
Advancing Inclusive Healthcare Strategies Through Social Impact and Sustainability
In this update we examine how Novartis is embedding inclusive healthcare strategies into its core business by launching ambitious long-term Social Impact and Sustainability (SI&S) targets that reach to 2040. These targets integrate innovation, access to medicines, global health, environmental...
Closing the East-West Divide: Addressing Healthcare Investment Disparities in Central and Eastern...
A recent study commissioned by EFPIA and authored by leading CEE academics—Dr. Slaveyko Djambazov, Dr. Luka Voncina, Dr. Aleš Rod, and Dr. Marcin Czech—reveals that despite accelerated public health spending growth in several CEE countries, structural underinvestment persists. This produces marke...
Safeguarding Access: Navigating Pharmaceutical Cost Pressures in Portugal
Pharmaceutical cost pressures are mounting in Portugal, with industry leaders warning that price increases for certain medicines appear inevitable in the medium term despite the government’s commitment to strict controls in the 2026 annual review.
Global Cost Drivers Threaten Generic...